Hochstetler J A, Kreder K J, Brown C K, Loening S A
Department of Urology, University of Iowa Hospitals and Clinics, Iowa-City 52242-1089, USA.
Prostate. 1995 Jun;26(6):316-24. doi: 10.1002/pros.2990260607.
Between 1984 and 1991, a total of 177 patients with adenocarcinoma of the prostate were treated with transcutaneous, transperineal radioactive gold seeds. Of these 177 patients, 20 were determined to have pelvic lymph node involvement and were excluded from this review. The remaining 157 patients received a median radioactivity dose of 164 mCi with a median follow-up of 48 months. Cancer-specific survival at 5 years was 100% for stage A2 and B1, 90% for stage B2, and 76% for stage C cancer. Covariates of grade, total radioactivity administered, age of the patient, and number of seeds implanted did not influence disease-free survival in a statistically significant manner. Significant complications were observed in two patients. The survival rates of patients treated with 198Au seed implantation for localized cancer are equivalent or better when compared to historical data of patients treated with 125I implantation, external beam radiotherapy, combination radioactive gold seed implantation and external irradiation, and radical prostatectomy. In addition, these comparable survival rates using interstitial 198Au seeds may be achieved with less morbidity.
1984年至1991年间，共有177例前列腺腺癌患者接受了经皮、经会阴放射性金种子植入治疗。在这177例患者中，有20例被确定有盆腔淋巴结受累，被排除在本综述之外。其余157例患者接受的放射性剂量中位数为164毫居里，中位随访时间为48个月。A2期和B1期患者的5年癌症特异性生存率为100%，B2期为90%，C期癌症为76%。分级、给予的总放射性、患者年龄和植入的种子数量等协变量对无病生存率没有统计学上的显著影响。两名患者出现了严重并发症。与接受125I植入、外照射放疗、联合放射性金种子植入和外照射以及根治性前列腺切除术的患者的历史数据相比，用198Au种子植入治疗局限性癌症的患者的生存率相当或更高。此外，使用间质198Au种子获得这些相当的生存率时，发病率可能更低。
